Global Colorectal Cancer Drugs Market

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

The dermatitis market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex, and also synthetic equivalents of these hormones. The different routes of administrations include topical, oral, injectable and is used in cancer, blood disorders, chronic diseases, infectious diseases. It is distributed through various channels such as hospital, retail pharmacies, drug stores, online or mail pharmacies The global dermatitis market size is expected to grow from $5.92 billion in 2021 to $6.37 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global dermatitis market is expected to reach $8.06 billion in 2026 at a CAGR of 6.1%. Growth in atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). In order to find the efficacy and efficiency of drug, it has to be tried on the every type of patients. The effects of certain drugs in adults are quite different than in children, as a reason result of the clinical trial cannot be used for the production of drug that will be served to the children. This hinders the research and requires more efforts in clearing regulation set by FDA. For example, as the patient population is largely children, FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation is in compliance with Children’s Health Act of 2000 that requires all the children subjected to clinical trial be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business. For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also Biofrontera, Inc., a specialist in dermatology market acquired Cutanea Life Sciences, Inc.in 2019 for $7.3 million to increase their capital base and scale the business. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) that carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes makes the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan Plc. (Republic of Ireland) and Bristol-Myers Squibb. North America is the largest region in the dermatitis market in 2021. The Middle East is expected to be the fastest growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online or Mail Pharmacies 3) By Route of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability. The main drug class of multiple sclerosis drugs are immunomodulators, immunosuppressants, interferons and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various route of administration includes oral drugs and parenteral drugs that are distributed through hospital pharmacy, retail pharmacy and online stores. The global multiple sclerosis drugs market size is expected to grow from $24.75 billion in 2021 to $26.29 billion in 2022 at a compound annual growth rate (CAGR) of 6.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MS drugs market is expected to reach $33.46 billion in 2026 at a CAGR of 6.2%. The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested $1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market. The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. As reported by Institute for Clinical and Economic Review (ICER), the MS drugs costs roughly between $63,000 and $104,000 annually. For instance, in 2019, after receiving criticism by National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to $88,000 per year in order to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market. The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug. In 2019, Bristol-Myers Squibb, a USA based pharmaceutical company, acquired Celgene for $74 billion. Through the acquisition Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of the Celgene’s pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceutical, EMD Serono, AbbVie Inc., Betaseron, CinnoVex, Extavia, Rebif and Tysabr. North America was the largest region in the multiple sclerosis drug market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global multiple sclerosis drugs market is segmented - 1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Others 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Stores 3) By Route of Administration: Oral Drugs, Parenteral Drugs

The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process. The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and the various distribution channel involved are hospital pharmacy, retail pharmacy and online pharmacy. The global oncology biosimilars market size is expected to grow from $3.27 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 28.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oncology biosimilars market is expected to reach $11.35 billion in 2026 at a CAGR of 28.3%. The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus' plan is to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan and F Hoffmann-La Roche. North America was the largest region in the oncology biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Others 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

The cancer biologics market consists of sales of cancer biologics. Cancer biologic drugs are the products that are produced from living organisms or contain components of a living organisms. Biologic drugs include a wide variety of products which are derived from human, animal or microorganisms by using biotechnology. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancers, others and distributed through various channels such as hospitals, clinics, others. The global cancer biologics market size is expected to grow from $76.46 billion in 2021 to $86.64 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer biologics market is expected to reach $129.05 billion in 2026 at a CAGR of 10.5%. Rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market growth. Chronic disorders are the diseases which persists over a long period of time and hinder the health of people with disabilities and cancer is one of the common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to World Health Organization (WHO), in 2020 chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion as they are proteins which are quickly digested and inactivated if given by mouth so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers which help the physicians to decide the treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy. According to FDA approval process of new cancer treatment and biological products, the application for the approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from a number of alternative sources. In May 2019, Evotec SE, drug discovery and development solutions provider acquired Just Biotherapeutics, Inc. for $90 million. The acquisition will help Evotec's business to grow into offering the biologics into the therapeutic areas such as oncology. Just Biotherapeutics is a US-based unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for development and manufacturing of biologics at highest standards. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis and Pfizer. North America was the largest region in the cancer biologics market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Others 2) By Application: Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Others 3) By Distribution Channel: Hospitals, Clinics, Others

The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors. Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth. The main types of treatments in HER2 inhibitor are monotherapy and combination therapy. Monotherapy refers to the use of a single medicine to treat a specific condition or disease. The different applications include squamous cell carcinoma, adenocarcinoma, large cell carcinoma, breast cancer, others and involves several sectors such as hospitals, clinics, others. The global HER2 inhibitors market size is expected to grow from $6.61 billion in 2021 to $7.26 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The HER2 inhibitors market is expected to reach $10.60 billion in 2026 at a CAGR of 9.9%. The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed their treatment. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years. High costs associated with the HER-2 inhibitors treatment is a major issue faced by citizens of many countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. Trastuzumab, a licensed HER2 inhibitor, has been the most expensive systemic cancer therapy procedure at a variety of disease sites. In 2019, the cost of trastuzumab in India ranged from $774.6 to $841.35 per 440 mg vial. In patients with HER 2 positive early breast cancer, nearly 18 cycles of therapy based on trastuzumab are needed that further charge more than $1,335.52 in India. Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market. Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitors market. There have been several partnerships in recent years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology. In 2019, Daiichi Sankyo announced its collaboration with AstraZeneca for development and commercialization collaboration for Daiichi Sankyo’s HER2 targeting antibody drug conjugate. In August 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation acquired Trillium Therapeutics Inc for an undisclosed amount. This acquisition of Trillium will build a robust record of leadership in oncology, enhancing the hematology portfolio to enhance outcomes for people living with blood cancers worldwide. Trillium Therapeutics Inc is a Canada-based company that develops therapies for the treatment of cancer. Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan and Biocon. North America was the largest region in the HER2 inhibitors market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the HER2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the HER2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global HER2 inhibitors market is segmented - 1) By Treatment: Monotherapy, Combination Therapy 2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Others 3) By End-User: Hospitals, Clinics, Others

The vascular endothelial growth factor inhibitor market consists of sales of vascular endothelial growth factor inhibitor biosimilars. Vascular endothelial growth factor (VEGF)/vascular endothelial growth factor (VEGFR) inhibitors are agents that inhibit VEGF and VEGFR activity. VEGF is an essential growth factor that promotes the growth of new blood vessels. The main types in vascular endothelial growth factor (VEGF) inhibitor are avastin, tecentriq, cometriq, eylea and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problem and other retinal issues. It is administered into the eye to assist delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, intravenous and is used in oncology, ophthalmology, others. The global vascular endothelial growth factor inhibitor market is expected to grow from $7.51 billion in 2021 to $8.27 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The VEGF inhibitor market is expected to reach $11.30 billion in 2026 at a CAGR of 8.1%. The growing prevalence of cancer and macular degeneration disease is expected to drive the vascular endothelial growth factor (VEGF) inhibitor market. For instance, according to this systematic review and meta-analysis, age-related macular degeneration affects 8-7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Furthermore, according to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. Vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the growth of the vascular endothelial growth factor inhibitor market over the forecast period. Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinders the growth of the VEGF inhibitor market. Key players operating in the industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in May 2020, AbbVie, a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company focused on eye care. This acquisition establishes a biopharma firm with leadership roles in vital therapeutic areas such as hematologic oncology, immunology, Allergan Aesthetics and neuroscience. Furthermore, in January 2020, Exonate, a biotechnology company, collaborated with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson for the development of a new eye drop for the treatment of retinal vascular diseases. Exonate developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for an amount of $63 billion. This acquisition is expected to give AbbVie Inc. an enhanced long-term growth potential along with a growing dividend and investment in innovation in each of Allergan plc therapeutic categories. Allergan plc is an Ireland-based pharmaceutical company engaged in the manufacturing of drugs and medical devices in the field of eye care, medical aesthetics, gastroenterology, and the central nervous system. Major players in the vascular endothelial growth factor (VEGF) inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca plc, Bayer AG, Eli Lilly and Company and Allergan plc. North America was the largest region in the vascular endothelial growth factor inhibitor market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the VEGF inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global vascular endothelial growth factor (VEGF) inhibitor market is segmented - 1) By Drug Type: Avastin, Tecentriq, Cometriq, Eylea, Others 2) By Route of Administration: Oral, Intravenous 3) By Application: Oncology, Ophthalmology, Others

The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders. The main technologies of antisense & RNAi therapeutics are RNA interference, antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various route of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other. The global antisense & RNAI therapeutics market size is expected to grow from $1.32 billion in 2021 to $1.42 billion in 2022 at a compound annual growth rate (CAGR) of 8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antisense and RNAi therapeutics market is expected to reach $2.14 billion in 2026 at a CAGR of 10.8%. The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease is the most common neurodegenerative diseases affecting millions of people globally. In the USA, around 930,000 people had Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of 2019 health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market. The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years. Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro's CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs). In November 2019, Novartis International AG, a Switzerland-based pharmaceutical company acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7 million. With the acquisition of The Medicines Company, Novartis International AG plans to enter RNA therapeutics by acquiring its last stage RNA interference drug designed for protection against cardiovascular diseases in twice-yearly shorts. The drug has met the primary endpoint in the three phases of clinical trials and is approved for the treatment of cardiovascular diseases in the USA in 2019 and the EU in early 2020. The Medicines Company is a US-based company focused on the development of RNA drug inclisiran that is used in the treatment of renal impairment and cardiovascular diseases. Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global antisense & RNAi therapeutics market is segmented - 1) By Technology: RNA Interference, Antisense RNA 2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-Dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Others